livemint.com
69%
495
Covid, chronic drugs drive domestic pharma sales in Q3
₹1,370 crore, with chronic drug sales, which make up 65% of the company’s domestic revenue, growing 12.9% Covid-19 drugs and chronic drugs such as anti-diabetics shored up domestic sales for pharmaceutical companies in the October-December quarter.Consolidated net profits of Sun Pharmaceutical Industries Ltd, Lupin Ltd and Cipla Ltd during the quarter doubled from a year ago, with sales growth in India aided primarily by chronic drugs for the first two and covid-19 medicines for Cipla. Dr Reddy’s Laboratories had a weak quarter compared to the other three, primarily because of a ₹600 crore impairment on certain products it had acquired.